Abstract
Transoral robotic surgery (TORS) has been advocated as a means of de-escalating or “personalizing” adjuvant treatment of oropharyngeal squamous cell carcinoma (OSCC) based upon known histopathological risk factors. Despite its favorable prognosis, approximately 9-14% of patients with HPV-related OSCC will still fail conventional therapy. Accumulating evidence points to the importance of an ongoing antitumor T cell response and tumor infiltration by active effector T cells prior to conventional therapy like surgery, chemotherapy or radiotherapy that corresponds with clinical outcome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
